Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-02-28

Study Completion Date

2003-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study looks at how effective acid suppression therapy is on symptoms associated with chronic posterior laryngitis (CPL) in patients with documented pharyngeal acid reflux.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux

NCT00369265

Laryngopharyngeal Reflux

TERMINATED PHASE4

Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment

NCT00204698

Laryngopharyngeal Reflux

COMPLETED PHASE2/PHASE3

Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction

NCT04383262

Laryngopharyngeal Reflux

NOT_YET_RECRUITING PHASE2

Comparison of Voice Therapy and Antireflex Therapy in LPR

NCT02530879

Laryngopharyngeal Reflux

WITHDRAWN PHASE4

Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas

NCT00567658

Larynx Disease

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Posterior Laryngitis (CPL)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

Esomeprazole

Intervention Type DRUG

40mg orally twice daily

2

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Esomeprazole

40mg orally twice daily

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nexium

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* One or more of the following symptoms present for at least 3 consecutive months: throat clearing, cough, globus, sore throat, or hoarseness.
* Must have a total score of 5 or more on the Chronic Posterior Laryngitis Index (CPLI) grading system.

Exclusion Criteria

* A number of diseases / conditions would preclude a patient from taking part in the study, as listed in the protocol.
* If the patient is on certain medications this will also preclude them from taking part.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No